Advertisement
New Zealand markets closed
  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     
  • NZD/USD

    0.5937
    0.0000 (-0.00%)
     
  • NZD/EUR

    0.5545
    -0.0000 (-0.01%)
     
  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     
  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     
  • OIL

    82.64
    -0.17 (-0.21%)
     
  • GOLD

    2,329.00
    -9.40 (-0.40%)
     
  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     
  • FTSE

    8,040.38
    -4.43 (-0.06%)
     
  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     
  • DAX

    18,088.70
    -48.95 (-0.27%)
     
  • Hang Seng

    17,201.27
    +372.34 (+2.21%)
     
  • NIKKEI 225

    38,013.46
    -446.62 (-1.16%)
     
  • NZD/JPY

    92.2110
    +0.0960 (+0.10%)
     

How Is Jazz Pharmaceuticals’ Xyrem Positioned after 3Q17?

In 3Q17, Jazz Pharmaceuticals’ (JAZZ) Xyrem generated revenue of $303.9 million, which reflected a rise of ~6% on a YoY (year-over-year) basis.